Kyttaro signs licence agreement with Lilly for monoclonal antibody programme
The monoclonal antibody will also be developed to treat several other conditions including ASCVD-related dyslipidemias: hypertriglyceridemia and hypercholesterolemia
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
12 Apr 22
The monoclonal antibody will also be developed to treat several other conditions including ASCVD-related dyslipidemias: hypertriglyceridemia and hypercholesterolemia
11 Apr 22
The recalled vaccines form the lot were supplied in Norway, Poland, Portugal, Spain and Sweden from 13 to…
11 Apr 22
The vaccine will be produced by SII under the brand name Covovax and is authorised for active immunisation…
08 Apr 22
The proposed acquisition will boost Pfizer’s expertise in infectious disease research and development by providing a complementary approach…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 Apr 22
The EC approval is based on pivotal findings from the double-blind, randomised, placebo-controlled Phase III VOYAGE clinical trial…
07 Apr 22
The transaction will create a vertically integrated platform and cardiovascular disease franchise, which will support the discovery and…
07 Apr 22
The US FDA approval was based on positive results from EPIK-P1, a retrospective chart review study of Vijoice…
06 Apr 22
The MAST platform provides real-time process information, reduces the process development time by half, and lowers costs
06 Apr 22
The expanded collaboration will combine Takeda’s expertise in the rare disease space with Evozyne’s protein engineering capabilities
05 Apr 22
The US FDA has accepted the company’s supplemental Biologics License Application (sBLA) for tocilizumab and is expected to…